Patient Focused Drug Development: Eczema

Treatment priorities of people living with atopic dermatitis (AD)—or eczema— are at the core of a special initiative called “More Than Skin Deep.”

AAFA partnered with four nonprofit organizations to create a series of opportunities for your perspective to inform and shape development of drugs and medical devices designed to treat eczema.

As part of the collaboration, we hosted a patient-focused drug development (PFDD) meeting on September 23, 2019 in the Washington, D.C. area. It provided the eczema community an opportunity to speak directly to Food and Drug Administration (FDA) staff, representatives of pharmaceutical and medical device companies, and other key stakeholders.

This initiative was the first of its kind for eczema . Your voice and perspectives are essential for us to demonstrate that eczema is “more than skin deep.”